Prokarium & Wacker Biotech Sign Manufacturing Contract for Bladder Cancer Immunotherapy

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Wacker Biotech have signed a contract for the manufacturing of Prokarium’s microbial novel immunotherapy for bladder cancer.
 
Wacker Biotech will ramp up GMP (Good Manufacturing Practice) production of Prokarium’s Salmonella-based immunotherapy at its biotech site in Amsterdam using its LIBATEC technology.
 
Preparations for the start of production, technology transfer and scale-up for a Phase 1 trial are already underway, as announced by the companies.
 
“We are very pleased to work with Wacker Biotech given their deep expertise with live microbial products and GMP production,” said Kristen Albright, PharmD, Prokarium’s chief executive officer. “This marks an exciting milestone essential to progressing our lead microbial immunotherapy program into clinic.”
 
As a CDMO (Contract Development and Manufacturing Organization), Wacker Biotech will use its LIBATEC technology platform for Live Microbial Products (LMPs) in the project. The company’s site in Amsterdam is a pioneer in the field of LMP production.
 
“With our LIBATEC platform, Wacker Biotech offers its customers over 15 years’ experience in process development and manufacturing pharmaceuticals that contain living microorganisms,” said Jörg Lindemann, managing director of Wacker Biotech B.V. “The LIBATEC platform can be used for a wide range of Live Microbial Products and is perfectly suited to support Prokarium with their Salmonella-based immunotherapy.”